Audio Journal of Oncology Podcast

ASH 2025: Measurable Residual Disease Can Predict Overall Survival in Patients with Acute Myeloid Leukemia

An interview with: Jesse Tettero MD PhD, Amsterdam University Medical Center, Department of Hematology, Amsterdam, Netherlands and: Virginia Tech FBRI Cancer Research Center, Fralin Biomedical Research Institute, Washington, USA.

Reporting from: American Society of Hematology 2025 Annual Meeting, Orlando, USA

ORLANDO, USA—Measurable residual disease (MRD) could soon emerge as a key surrogate endpoint in clinical studies of acute myeloid leukemia indicating overall survival, and speed the introduction of effective new agents. That’s according to findings from the HARMONY Alli...

Next Generation Sequencing-Assessed Minimum Residual Disease Identifies Young Patients with High-risk/Relapsed B-cell Acute Lymphoblastic Lymphomas Who Can Omit Pre-Transplant Total Body Irradiation

An interview with:

Hisham Abdel-Azim MD MS, Chief, Division of Transplant/Cell Therapy and Hematological Malignancies, Cancer Center, Departments of Pediatrics and Medicine, Loma Linda University School of Medicine, Children Hospital and Medical Center, Loma Linda CA, United States

ORLANDO, Florida—Total body irradiation before allogeneic hematopoietic cell transplantation can be avoided in patients with B-cell lymphomas if you monitor their initial treatment responses by assessing minimum residual disease using ne...

2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings

An interview with: Aditya Bardia MD MPH, Professor of Medicine and Director of Translational Research Integration, University of California, Los Angeles and Jonsson Comprehensive Cancer Center, Los Angeles, California USA.

SAN ANTONIO, USA—Significant and clinically meaningful improvements in disease-free survival were reported from the Phase III lidERA Breast Cancer trial at the 2025 San Antonio Breast Cancer Symposium, in San Antonio, USA.  First author of the...

ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke. “Financial Toxicity” is Often More Worrying than you Child’s Cancer

An interview with: Daniel J Zheng MD, MHS, MSHP, Instructor, Children’s Hospital of Philadelphia, Attending Oncologist, Division of Oncology, Philadelphia PA, United States

ORLANDO, USA—Although most children with acute lymphoblastic leukemia can look forward to a cure, their families may face catastrophic financial hardship, according to Daniel Zheng, an Instructor and Attending Oncologist at the Division of Oncology, Children’s Hospital of Philadelphia in Philadelphia, PA, United States. After reporting on the challenge families face of “fin...

https://www.audiomedica.com/wp-content/2025/12/251209-0900-Peihua-Lu-Robert-Chiesa-C2998-Discussion-at-ASH-AJO-PRODUCTION-MASTER.mp3Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies

A discussion interview with Peihua Lu MD from Lu Daopei Hospital in Beijing, China and Robert Chiesa MD PhD from Great Ormond Street Hospital for Children, London, UK, at the American Society of Hematology Annual Meeting in Orlando, Florida, USA

ORLANDO, USA—Children and young adults whose T-cell malignancies had become refractory to all standard treatments have been rescued by means of two different chimeric antigen receptor T-cell therapies: one develo...

An interview with Jeanne Tie MD, Medical Oncologist, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.

BERLIN, Germany—Liquid biopsy as a means of monitoring disease control in patients with stage three colon cancer has been investigated in a study from Melbourne, Australia reported to the 2025 Annual Congress of the European Society for Medical Oncology, ESMO. The aim was to discover whether patients with ctDNA negative biopsy findings could safely avoid chemotherapy and be spared toxicities including neuropathy.

After reporting findings from the AGITG DYNAMIC-III tr...

Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer

An interview with: Paul H Cottu MD PhD, Medical Oncologist and Associate Professor, Institute Curie, Paris, France

BERLIN, Germany—Patients with high-risk, hormone receptor positive, HER2 negative early breast cancers, who would typically be candidates for chemotherapy, had good clinical responses, high biological responses and good rates of surgery in a clinical trial using a chemotherapy-free neoadjuvant regimen consisting of letrozole hormone therapy plus abemaciclib CDK 4/6 inhibition.

Medical Oncologist Paul Cottu MD PhD from th...

An interview with Li Zhang MD, Medical Oncologist and Full Professor, Sun Yat-sen University Cancer Center, Guangzhou, China

BERLIN, Germany—A doubling of progression-free survival, and highly statistically significant benefit for overall survival, has been achieved in patients with epidermal growth factor- (EGFR-) mutated non-small cell lung cancers that had become refractory to EGFR tyrosine kinase inhibitor therapy in a study in which treatment with the antibody drug conjugate (ADC) sacituzumab tirumotecan was compared with standard platinum-based chemotherapy.

At the 2025 Annual Congress of the European Society for Medical Oncology (ESMO) Professor Li Zhang MD, a me...

An interview with: https://www.audiomedica.com/wp-content/2025/11/251019-Erwei-Song-ESMO-2025-PRODUCTION-MASTER.mp3, Director of Health Science Center, President, Sun Yat-sen Memorial Hospital, Guangzhou (SYSU), Guangzhou, China.

BERLIN, Germany—The open-label HORIZON-Breast01 phase-three study has reported early data showing that, for previously treated patients with advanced or metastatic breast cancer, progression-free survival improved from a median of 8.3 months with pyrotinib plus capecitabine standard of care to 30.6 months among patients in the experimental arm who received monotherapy with the new antibody drug conjugate (ADC) trastuzumab resetecan. Furthermore, the ADC had a favorable safety profile with low occurrence of interstitial lung di...

An interview with: Andrew Clamp MD, PhD, Consultant Medical Oncologist, Christie Hospital, Manchester, UK

BERLIN, Germany—An important therapeutic gain in terms of overall- and progression-free survival has been achieved merely by changing the chemotherapy dose schedule given to patients with high-risk stage three or four epithelial ovarian cancer.

This was reported from the ICON8B: GCIG phase-three randomised trial by Andrew Clamp MD PhD of the Christie Hospital in Manchester, England, at the 2025 Annual Congress of the European Society for Medical Oncology. Dr. Clamp discussed the findings with our reporter, Peter Goodwin.

Au...

An interview with Nima Nabavizadeh MD, Associate Professor of Radiation Medicine, Oregon Health & Science University (OHSU), Portland, USA, Chief Medical Officer, Cancer Early Detection Research Center, Portland, Oregon.https://www.audiomedica.com/wp-content/2025/11/251107-Nima-Nabavizadeh-MD-ESMO-2024-PRODUCTION-MASTER.mp3

BERLIN, Germany—A pan-cancer early detection test, that identifies “methylation fingerprints” for a wide range of cancers, has been shown to find more cancers sooner than conventional screening according to research reported to the European Society for Medical Oncology (ESMO) 2025 Annual Congress.

Nima Nabavizadeh MD, Associate Professor of Radiation Medicine at the Oregon Health & Science University (OHSU) in Portland, USA, w...

An interview with: Xiuning Le MD PhD, Medical Oncologist, Department of Thoracic Medicine, UT MD Anderson Cancer Center, Houston TX

BERLIN, Germany—Mutations in the HER2 molecule can be found in a few per cent of non-small cell lung cancers, and these can now be targeted by the new drug sevabertinib that can bring benefit to patients who have the mutation. That’s according to findings from the SOHO-01 study reported at the 2025 Annual Congress of the European Society of Clinical Oncology.

After her talk at the congress, first author Xiuning Le MD PhD, who is a...

An interview with: Christof Vulsteke MD PhD, Medical Oncologist, Head of the Integrated Cancer Center Ghent, Belgium

BERLIN, Germany—Patients with muscle invasive bladder who were ineligible for cisplatin chemotherapy gained large, clinically meaningful and statistically significant benefits from treatment with the antibody drug conjugate enfortumab vedotin combined with pembrolizumab checkpoint inhibition in the phase three KEYNOTE-905 study.

At the 2025 Annual Congress of the European Society for Medical Oncology (ESMO) Medical Oncologist Christof Vulsteke, Head of the Integrated Cancer Centre in Ghent, Belgium, reported marked improvements of event-free and overall survival among patients treated with th...

An interview with: Xichun Hu MD PhD, Professor, Director, Department of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China

BERLIN, Germany—In a head-to-head comparison of two antibody drug conjugates used to treat unresectable or metastatic breast cancer, patients treated with trastuzumab botidotin lived more than twice as long before disease progression than those in the control arm receiving trastuzumab emtansine (T-DM1).  This finding was announced by Chinese researchers at the 2025 Annual Congress of the European Society of Medical Oncology.

Lead author Xichun Hu MD PhD, Professor, Director, Department of Medical Oncology, Shanghai Cancer Cen...

An interview with: Martin Wermke MD, TU Dresden, NCT/UCC Early Clinical Trial Unit and Medical Clinic, Poliklinik I, Natural Centre for Tumor Diseases, Dresden, Germany

BERLIN, Germany—The prospect of markedly better outcomes for patients with small cell lung cancer, with “encouraging initial survival outcomes”, was raised by findings from the DeLLphi-303 study, reported at the European Society for Medical Oncology (ESMO) 2025 Annual Congress. The bi-specific T-cell engager drug tarlatamab was included with initial therapy for patients with extensive stage small cell lung cancer.

Martin Wermke MD, from TU Dresden, Director of the NCT/UCC Ea...

An interview with:  John P. Crown MD MBA, Consultant Medical Oncologist, St. Vincent’s University Hospital, Dublin, Professor of Translational Cancer Research, Dublin City University, Professor of Medicine, University College Dublin   Ireland.

BERLIN, Germany—Patients with high-risk node-negative ER-positive HER2-negative early breast cancer who had the CDK 4/6 inhibitor drug ribociclib added to their non-steroidal aromatase inhibitor (AI) adjuvant therapy after surgery had significantly longer freedom from progression to invasive disease compared with patients receiving the AI alone.  This is according to five-year data from the NATALEE trial reported at the 2025 Annual Congress of the European Society for Medi...

An interview with: Javier C Cortés MD PhD, Breast Cancer Medical Oncologist, IOB Madrid, Institute of Oncology, Madrid, and International Breast Cancer Centre, Barcelona, Spain

BERLIN, Germany—Treatment with the antibody drug conjugate (ADC) sacituzumab govitecan (that targets the Trop-2 cancer-associated protein, delivering a cytotoxic topoisomerase inhibitor payload) has significantly improved progression-free survival in patients with newly-diagnosed metastatic triple-negative breast cancer who were not candidates for treatment with immune checkpoint inhibition and had received no prior therapy.

At the European Society for Medical Oncology (ESMO) 2025 Annual Congress Javier C Cortés MD PhD from the...

An interview with:

Trevor Leong  MD, Peter McCallum Cancer Centre, Radiation Oncology Department, Melbourne, Australia

BARCELONA, Spain—Although pre-operative radiotherapy brought better response rates in patients resected for their gastric or GE-junction adenocarcinomas, there was no improvement in survival. This is the clear finding from a big, long-term study led by an Australian team.

The multi-continent, phase-three randomized TOP GEAR trial, headquartered in Sydney Australia, definitively found no benefit for overall or progression-free survival from adding radiation before surgery.

This clear finding was announced at the 2024 Annual Meeti...

An interview with: Domenica Lorusso MD PhD, Director of the Gynaecological Oncology Unit, full Professor of Obstetrics and Gynaecology, Humanitas Hospital San Pio X, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.

Both overall and progression-free survival were significantly improved when the anti-PD-1 agent pembrolizumab was added to standard chemoradiotherapy as initial treatment for patients with high-risk locally advanced cervical cancer.

Results from the randomized, double-blind, phase III KEYNOTE-A18 study of immunotherapy, used together with standard concurrent chemoradiotherapy among 1060 patients, were reported by a multinational team of researchers led...

An interview with:

James Larkin FRCP, PhD, Medical Oncologist, Professor, Royal Marsden Hospital, London

Checkpoint inhibitor therapy for advanced melanoma has achieved sustained responses and long-term overall survival, transforming the prognosis for as many as half of all patients. 10-year survival outcomes from the phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma were reported at the 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) held in Barcelona.

Peter Goodwin, talked with study author, James Larkin FRCP PhD, Professor and Medical Oncologist at the Royal Marsden Hospital in London.<...

An interview with: Jefferson DeKloe BSc, Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA

CHICAGO, USA—Although the take-up of vaccination for human papilloma virus (HPV) among girls and boys in the USA has been lower than in many other industrial countries, American researchers have now shown clearly that in addition to the prevention of cervical cancer in women, men have also been protected against HPV-related cancers.

At the 2024 American Society of Clinical Oncology Annual (ASCO) Meeting in Chicago a new study of HPV vaccination of girls and boys in the United States revealed a re...

An interview with Rebecca Dent MD, Deputy Chief Executive Officer, National Cancer Centre, Singapore, ESMO 2024 Scientific Chair.

ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……”

BARCELONA, Spain—At the last Annual Meeting of the European Society for Medical Oncology (ESMO), medical oncologist Rebecca Dent MD, Deputy Chief Executive Officer at the National Cancer Centre in Singapore, told Peter Goodwin what had, for her, been the key areas of progress in cancer medicine announced at the meeting in which significant advances had been made.

Audio Journal...

Audio Journal of Oncology interview with:

Bart Neyns MD PhD, Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy, Medical Oncology Department, Brussels, Belgium

 BARCELONA, Spain—Intracranial administration of autologous dendritic cells was combined with combination checkpoint inhibition in a phase 1 study of patients with recurrent glioblastoma that reported marked clinical responses to the European Society for Medical Oncology (ESMO) annual meeting in Barcelona.

Cells harvested from each patient were injected directly into the brain tissue resection cavity lining after surgery. Patients also received intra-cranial injections of the checkpoint inhibitor combination: nivolumab plus ipilimumab.

An interview with:

Victor Velculescu MD PhD, Co-director, Cancer Genetics & Epigenetics Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

SAN DIEGO, USA—A blood test using an artificial intelligence DNA pattern recognition system that brings earlier, more certain detection of ovarian cancer was reported at the American Association for Cancer Research Annual Meeting held in San Diego.

The test analyses patterns of fragments of circulating DNA (called DNA fragmentomes). When combined with analysis of circulating tumor protein markers these were found to be highly correlated with ov...

Audio Journal of Oncology: Sept 23rd, 2025

An interview with:

Timothy Yap MD PhD MBBS, Professor of Investigational Cancer Therapeutics, Head of Clinical Development, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, USA

SAN DIEGO, USA—Breast, ovarian, pancreatic, prostate and other solid tumors with mutations sensitizing them to poly ADP ribose polymerase (PARP) inhibition, could potentially be controlled better and with less toxicity with the new selective PARP-1 inhibitor saruparib than with existing licensed agents which inhibit both PARP 1 and PARP 2. That’s according to early results from the PETRA stud...

Interviews with:

Stacey A.  Kenfield ScD, Epidemiologist, Professor of Urology, Epidemiology and Biostatistics, and June Chan ScD, Cancer Epidemiologist, Department of Epibiostat and Urology, University of California San Francisco, California USA.

 SAN DIEGO, USA—Physical exercise keeps patients with prostate cancer alive longer, according to a combination of epidemiological and clinical study evidence emerging from research in San Francisco, California.

Intervention study findings reported at the American Association for Cancer Research (AACR) Annual Meeting in San Diego are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or m...

An interview with Jonathan T. Yang MD PhD, Washington University, Seattle, USA, (Formerly of Memorial Sloan Kettering Cancer Center, New York.)

SAN DIEGO, USA—An international phase one clinical study has found that a drug known to inhibit DNA damage repair was able to boost the efficacy of radiotherapy in patients being treated for their glioblastoma.

The radiosensitizer, AZD1390, an inhibitor of ataxia telangiectasia mutated (ATM) kinase, was tested as adjunctive therapy (combined with standard radiation plus temozolomide) among 115 patients who had recurrent or newly diagnosed glioblastoma.

 First author Jonathan T. Yang MD PhD...

An interview with:

Heather McArthur MD MPH, Clinical Director Breast Cancer, Komen Distinguished Chair Clinical Breast Research, University of Texas Southwestern Medical Center, Dallas TX

MILAN, Italy—Adjuvant therapy with a checkpoint inhibitor did not benefit patients with triple negative breast cancer in a big new study reported to the 14th European Breast Cancer Conference in Milan, Italy.

Heather McArthur MD MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical Breast Research at the University of Texas Southwestern Medical Center, Dallas TX, told the conference that the ALEXANDRA/IMpassion030 phase 3 tr...

An interview with: Stefan Paepke MD, Interdisciplinary Breast Centre, Technical University of Munich, Germany, recorded at the 14th European Breast Cancer Conference, Milan, Italy.

MILAN, Italy—Women who need surgical implants after their mastectomy for breast cancer could now benefit from mesh-supported prosthetics that bring high rates of satisfaction and psychosocial well-being, with low complication rates. That’s according to findings from German PRO-Pocket-Trial, reported at the 14th European Breast Cancer Conference in Milan.

Study patients who had the new “tetanized” mesh-pocket-supported implants positioned by means of a “pre-pectoral” procedure found the technique prevented the unnatural br...

An interview with Sophie Bosma MD PhD, from The Netherlands Cancer Institute, Amsterdam recorded at the 14th European Breast Cancer Conference in Milan.

MILAN, Italy—The optimal radiation boost dose to protect young patients with early breast cancer has been investigated with ten years of follow up in the “Young Boost trial” conducted in the Netherlands. The study randomized between giving patients a low radiation dose as a boost to their standard radiotherapy or a high dose.

At the 14th European Breast Cancer Conference held in Milan Radiation Oncologist Sophie Bosma MD PhD, from The Nether...

An interview with: Adri Voogd PhD, Associate Professor of Clinical Epidemiology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

 MILAN, Italy—Although outcomes following breast conserving surgery (with or without radiotherapy) for ductal carcinoma in situ (DCIS) are excellent, it is still not clear which cases would never have progressed in all events.

A 30-year-long population-based epidemiology study reported to the 14th European Breast Cancer conference held in Milan has now brought some granular detailed data showing that breast conserving therapy had become increasingly effective in preventing the emergence of breast can...

An interview with Annemiek van Hemert MD PhD, Surgical Oncology Department, Antoni van Leeuwenhoek-Netherlands Cancer Institute (AVL-NKI), Amsterdam Netherlands

MILAN, Italy—Four out of five patients with extensive nodal spread of their breast cancer could be spared extensive axillary dissection, if a new method of marking lymph nodes is used. That’s according to the findings of a study from Amsterdam reported at the European Breast Cancer Conference held in Milan.

Annemiek van Hemert MD PhD, from the Surgical Oncology Department of the Antoni van Leeuwenhoek-Netherlands Cancer Institute (AVL-NKI) in Amsterdam, The Netherlands, reported her find...

An interview with:

Tim Rattay MBChB PhD, Consultant Breast Surgeon, University Hospitals of Leicester, Associate Professor in Breast Surgery, Leicester Cancer Research Centre, University of Leicester, England, UK. A report from the 14th European Breast Cancer Conference, Milan, Italy

MILAN, Italy—An artificial intelligence tool can predict the risk of lymphedema in a particular patient after breast cancer radiotherapy, according to research findings from Leicester University in the United Kingdom.

The 2024 European Breast Cancer Conference in Milan heard how AI can help cancer doctors to individualize radiotherapy regimens after surgery so as to mi...

An interview with Yasmin Civil MD PhD, UMC Hospital, Amsterdam, Netherlands.

MILAN, Italy—Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil MD PhD from the UMC Hospital in Amsterdam, who reported five-year results from the ABLATIVE trial of pre-operative MRI-guided single dose partial breast irradiation to the 14th European Breast Cancer Conference.

Partial breast irradiation, given before breast-conserving surgery, achieved durable pathologic complete remissions in low-risk breast cancer, and even held out the prospect of surgery-free treatment for some patients.

Af...

An interview with Heather McArthur MD MPH, Clinical Director of Breast Cancer, Komen Distinguished Chair in Clinical Breast Research, University of Texas Southwestern Medical Center, Dallas, USA

MILAN, Italy—Patients with early breast cancer testing positive for estrogen receptor (ER+) and negative for human epidermal growth factor receptor 2 (HER2-) had markedly better outcomes when immune checkpoint inhibitor therapy was added to their standard chemo- and endocrine therapies before and after surgery.

The KEYNOTE-756 phase 3 clinical trial found that patients benefited from having neo-adjuvant and adjuvant pembrolizumab regardless of their age or menopausal status.

...

An interview with:

Laura J. van ’t Veer PhD, Professor of Laboratory Medicine, Co-leader of the Breast Oncology Program, Director of Applied Genomics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.

MILAN, Italy—Around 25 per cent of patients with newly-diagnosed triple negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with pembrolizumab—even though it improves outcomes among the remaining majority. This finding comes from the I-SPY2 TRIAL and was reported at the 2024 European Breast Cancer Conference, held in Milan, Italy, by Laura van ’t Veer, Leader of the Breast Oncology...

Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer

Interviews with:

Érica A. Oliveira PhD, Senior Scientific Officer, Genomics and Evolutionary Dynamics, Institute of Cancer Research, Sutton, London UK

And:

Christopher Sng MD, Clinical Research Fellow, Institute of Cancer Research and Royal Marsden Hospital, London

LONDON, UK—New insights into understanding and overcoming cancer drug resistance have been announced by researchers from the Institute of Cancer Research and the Royal Marsden Hospital in London.

Érica Oliviera PhD, Senio...

Audio Journal of Oncology, August 5th, 2025

An interview with:

Christian Singer MD,

Head, Center for Breast Health, Department of Obstetrics & Gynecology, Comprehensive Cancer Center, Medical University of Vienna.

CHICAGO, USA—Your patients whose triple-negative breast cancers test positive for BRCA 1/2 mutations, could do better if you gave them the poly ADP ribose polymerase (PARP) inhibitor olaparib together with carboplatin, as neoadjuvant therapy, rather than a standard docetaxel/epirubicin/cyclophosphamide combination.

That’s according to the prospective randomized phase two ABCSG 45 trial reported by Austrian researchers at the 2025 Annua...

With:

Sara M Tolaney MD MPH, Chief, Division of Breast Oncology, Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard Medical School, Boston USA

And interviews with:

Rebecca Dent MD,

Deputy Chief Executive Officer, National Cancer Center, Singapore

And:

Giuseppe Curigliano MD PhD,

Director, Early Drug Development for Innovative Therapies Division, European Institute of Oncology, University of Milan, Milan, Italy

CHICAGO, USA—Patients with HER2 positive advanced or metastatic breast cancer lived significantly longer without having any return of their disease after treatment with a com...

Interview with Erica L. Mayer MD MPH, Director of Breast Cancer Clinical Research, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA.

With comment from:

Pat Price MD, Imperial College London, UK, Chair, Global Coalition for Radiotherapy.

CHICAGO, USA—Avoiding therapy discontinuation was the focus of the TRADE study looking at abemaciclib dose escalation among patients with early-stage hormone-receptor positive HER2 negative breast cancer.

At the 2025 Annual Meeting of the American Society of Clinical Oncology Erica L. Mayer MD MPH, Director of Breast Cancer Clinical Research at the Dana-Farber Cancer Institute in Bo...

An interview with:

David R Spigel FASCO, MD, Chief Scientific Officer, Sarah Cannon Research Institute, Nashville, Tennessee, US

With comment from:

Luis G Paz-Ares MD PhD

Chair of Medical Oncology, Hospital Universitario 12 de Octubre, Universitario de Madrid

 CHICAGO, USA—Although patients with early non-squamous non-small cell lung cancer can be cured by surgery alone, many are not. So, researchers in Nashville USA set up an international, multi-center, prospective randomized a study to examine whether a gene molecular assay could help by identifying patients at higher risk and treating them wit...

An interview with Jean Bourhis MD PhD, Head of Service of radiation oncology, Lausanne University Hospital, Lausanne, Switzerland.

And with:

Pat Price MD, Imperial College London, UK, Chair, Global Coalition for Radiotherapy.

SARAH MAXWELL

Disease free survival was extended in patients with head and neck cancers who had Nivolumab added to their standard post-operative therapy. I’m Sarah Maxwell. Welcome to this edition of the Audio Journal of Oncology.

Patients with high-risk cancers of the head and neck, had significant improvements in disease-free survival when treatment with the...

Audio Journal of Oncology

An interview with:

Luis G Paz-Ares MD PhD, Chair of Medical Oncology, Hospital Universitario 12 de Octubre, Universitario de Madrid

Comment by:

Julie R. Gralow MD FACP FASCO, Chief Medical Officer and Executive Vice President, American Society of Clinical Oncology.

https://www.audiomedica.com/wp-content/2025/06/Luis-Paz-Ares-PRODUCTION-MASTER-.mp3CHICAGO, USA—Patients with extensive stage small cell lung cancer had longer disease-free survival and lived longer when the drug lurbinectedin (a DNA damaging agent) was added to their maintenance therapy after induction using standard immunochemotherapy.  At the 2025 Annual Mee...

An interview with:

Elena Elez MD PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain

CHICAGO, USA—Adding the BRAF inhibitor encorafenib (partnered with EGFR-inhibitor cetuximab) to standard chemotherapy as initial therapy markedly delayed progression and extended life in patients whose inoperable metastatic colorectal cancers had tested positive for the BRAF V600E (found in around ten per cent of patients).  This was in the randomized open label phase three BREAKWATER study reported at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO).

After the ASCO conference, the Audio Journal of Oncol...

An interview with:  Yelena Y Janjigian MD, Medical Oncologist, Chief of Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York USA

CHICAGO—A treatment described as “practice-changing”, in which a combination of anti-PD-L1 immunotherapy and chemotherapy was used before and after surgery among patients with resectable gastric or gastroesophageal junction cancers, was reported from the MATTERHORN study at the Plenary Session of the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO).

First author, Medical Oncologist Yelena Y Janjigian MD, who is Chief of the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center in New Yor...

An interview with:

Christopher Booth, MD, FRCPC

Medical Oncologist and Professor, Queen’s University, Kingston, Canada

Comments from:

Rebecca Dent MD MSc,

Senior Consultant Medical Oncologist, Deputy Chief Executive Officer, National Cancer Centre, Singapore

CHICAGO— For patients with stage III and high-risk stage II colon cancer, a structured exercise program following surgery and adjuvant chemotherapy reduced the risk of recurrent or new cancer and increased survival in a study reported at the 2025 Annual Meeting of the American Society of Clinical Oncology. The long-term, large, randomized phase three Cana...

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota.

CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon cancer whose tumors tested positive for deficient mismatch repair.

At the American Society of Clinical Oncology 2025 Annual Meeting Frank Sinicrope reported findings from the phase three ATOMIC trial in which the immune checkpoint inhibitor atezolizumab was added to adjuvant chemotherapy after resection.

He discussed the study results with Audio Journal of Oncology correspondent Peter Goodwin:

INTERVIEW: Frank A Sinicrope MD, Mayo Clinic, Rochester, Mi...

An interview with:

Andy Zeng, MD/PhD candidate, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada

With comment from:

Hussein A Abbas MD PhD, Assistant Professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston TX 

CHICAGO—A research study using single-cell RNA sequencing data has created a new gene expression atlas that shows how normal hematopoietic cells differentiate. Findings reported at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) describe how it’s been used to catalog the multiple ways that aberrant differentiation can l...

An interview with:

Yelena Y Janjigian MD, Medical Oncologist, Chief of Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York.

CHICAGO, USA—Patients with early-stage solid cancers with DNA mismatch repair-deficiency (also known as microsatellite instability) benefitted greatly if they received anti-programmed death-1 (PD-1) immunotherapy with pembrolizumab after surgery and standard of care if they tested positive for circulating tumor DNA (ctDNA).

These findings come from a phase two clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research. Audio Journal of Oncology correspondent Peter Goodwin talked with first au...

The Audio Journal of Oncology talks with:

Paolo Marchetti MD, Scientific Director, Istituto Dermatopatico dell’Immacolata, Rome

And with:

Elaine R. Mardis, PhD FAACR, Co-Executive Director of the Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Rasmussen Nationwide Foundation Endowed Chair in Genomic Medicine, Professor of Pediatrics, Ohio State University College of Medicine, Columbus OH, USA.

CHICAGO, USA—Using a combination of tissue biopsy together with liquid biopsy seems to be the best way of providing samples for genomic profiling when you need to plan treatment for patien...

An Interview with:

Stephen Strickland, Jr. MD MSCI, Director, Leukemia Research; Executive Chair, Leukemia Research Committee, Sarah Cannon Research Instiute, Nashville, Tennessee USA

CHICAGO – Several patients with acute myeloid leukemia, who were treated with SENTI-202, a first-in-class chimeric antigen receptor (CAR) natural killer (NK) cell therapy, experienced complete remission after not responding to (or having relapsed following) prior treatments, according to interim results from the phase one SENTI-202-101 clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research.

During the conference Audio Journal of Oncology correspondent Peter Goodwin me...